title: Current Management of Hepatitis C Virus: Regimens for Peri-Liver Transplant Patients.
abstract: Chronic hepatitis C virus (HCV) infection currently remains the leading indication for liver transplant in the United States. However, recurrent HCV infection after transplant is universal in those who enter transplant with viremia resulting in reduced posttransplant graft and patient survival rates, caused in large part by progressive recurrent HCV disease. Therefore, successful treatment of HCV in the peri-transplant period, either before or after transplant, is paramount in ensuring improved posttransplant outcomes. This article reviews the experience to date treating HCV in wait-listed patients and liver transplant recipients and the unique challenges encountered when treating this population.
authors.affiliation: Division of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
authors.forename: Varun
authors.initials: V
authors.lastname: Saxena
authors.affiliation: Division of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA. Electronic address: norah.terrault@ucsf.edu.
authors.forename: Norah
authors.initials: N
authors.lastname: Terrault
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006085:Graft Survival; D019698:Hepatitis C, Chronic / Q000150:complications / Q000628:therapy*; D006801:Humans; D008103:Liver Cirrhosis / Q000503:physiopathology / Q000601:surgery / Q000821:virology; D016031:Liver Transplantation / Q000009:adverse effects; D019384:Nucleic Acid Synthesis Inhibitors / Q000627:therapeutic use*; D011182:Postoperative Care; D011300:Preoperative Care; D011480:Protease Inhibitors / Q000627:therapeutic use; D012367:RNA, Viral / Q000096:biosynthesis; D012008:Recurrence; D017361:Viral Nonstructural Proteins / Q000037:antagonists & inhibitors; D012324:RNA-Dependent RNA Polymerase
chemical_list: D000998:Antiviral Agents; D019384:Nucleic Acid Synthesis Inhibitors; D011480:Protease Inhibitors; D012367:RNA, Viral; D017361:Viral Nonstructural Proteins; C087036:NS-5 protein, hepatitis C virus; D012324:RNA-Dependent RNA Polymerase
keywords: Cholestatic hepatitis; Direct-acting antivirals; Hepatitis C virus; Ledipasvir; Liver transplant; Recurrent hepatitis C virus; Simeprevir; Sofosbuvir